(Reuters) -Amgen will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert ...

Mid-stage trial data showed Roche's experimental shot delivered weight loss on par with leading obesity treatments, ...

Add Yahoo as a preferred source to see more of our stories on Google. More than 2 out of 5 adults in the U.S. are considered obese, according to the Centers for Disease Control and Prevention. But ...

A genetic test may one day predict a child’s risk of obesity in adulthood, paving the way for early interventions. Certain genetic variants can affect how a person’s body stores fat or make them more ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

The future is uncertain — but your kid’s waistline as an adult might not be. Scientists have developed a groundbreaking test that can identify children as young as five who are at increased risk of ...

Scientists may have found a new way to spot early signs of obesity, which could lead to novel prevention strategies. A study ...

What if we could prevent people from developing obesity? The World Obesity Federation expects more than half the global population to develop overweight or obesity by 2035. However, treatment ...